Compare · BTAI vs ODT
BTAI vs ODT
Side-by-side comparison of BioXcel Therapeutics Inc. (BTAI) and Odonate Therapeutics Inc. (ODT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BTAI focuses on Biotechnology: Pharmaceutical Preparations, while ODT focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ODT is the larger of the two at $43.1M, about 1.9x BTAI ($23.2M).
- BTAI has hit the wire 8 times in the past 4 weeks while ODT has been quiet.
- BTAI has more recent analyst coverage (12 ratings vs 0 for ODT).
- Company
- BioXcel Therapeutics Inc.
- Odonate Therapeutics Inc.
- Price
- -
- -
- Market cap
- $23.2M
- $43.1M
- 1M return
- -13.54%
- -
- 1Y return
- -85.65%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2017
- News (4w)
- 8
- 0
- Recent ratings
- 12
- 0
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Odonate Therapeutics Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Latest BTAI
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 4 filed by Director Atkins Susan E.
- SEC Form 3 filed by new insider Atkins Susan E.
- Amendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Officer Rodriguez Javier converted options into 35 shares, increasing direct ownership by 0.13% to 26,838 units (SEC Form 4)
Latest ODT
- SEC Form 25-NSE filed by Odonate Therapeutics Inc.
- 60 Biggest Movers From Yesterday
- 56 Biggest Movers From Friday
- Odonate Therapeutics shares are trading lower after the company received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Stocks That Hit 52-Week Lows On Friday
- Odonate Therapeutics Announces Expected Delisting Of Stock
- Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Odonate Announces Expected Delisting of Its Stock
- Stocks That Hit 52-Week Lows On Thursday